Mesenchymal stem cell-derived exosomes in myocardial infarction: Therapeutic potential and application

Area of Science:

• Cardiovascular Biology
• Regenerative Medicine
• Biotechnology

Background:

• Myocardial infarction (MI) causes irreversible heart damage due to cardiomyocyte loss and scar formation, often from insufficient blood supply.
• Mesenchymal stem cells (MSCs) offer therapeutic benefits for MI, primarily through paracrine signaling.
• Exosomes, particularly those carrying microRNAs from MSCs, are potent mediators of cardiac function recovery post-MI.

Purpose of the Study:

• To review the biological characteristics of exosomes.
• To explore the therapeutic potential of exosomes in treating myocardial infarction.
• To discuss current strategies for optimizing exosome therapy for cardiac repair.

Main Methods:

• Literature review focusing on exosome biology and therapeutic applications in myocardial infarction.
• Analysis of exosome-derived microRNAs as key therapeutic components.
• Examination of current optimization strategies for exosome therapy.

Main Results:

• Exosomes, especially MSC-derived ones, are effective cell-free therapeutic agents for MI due to their composition and low immunogenicity.
• MicroRNAs within exosomes are crucial for promoting cardiac function recovery.
• Challenges remain in exosome stability and targeted delivery for clinical use.

Conclusions:

• Exosome therapy is a promising cell-free approach for myocardial infarction treatment.
• Optimizing exosome retention, targeting, and preparation (e.g., pre-treatment, transgenic modification) is essential for clinical translation.
• Further research into exosome characteristics and delivery is vital for advancing cardiac regenerative medicine.